Drugmakers raise US prices on over 250 medicines
NEW YORK CITY, New York: At the start of 2025, drug companies raised prices on over 250 brand-name medications in the U.S., including Pfizer's COVID-19 treatment Paxlovid, Bristol Myers Squibb's ...
Over 250 medicines to cost more from January 1 in the U.S; is your critical drug in the list? Check here
More than 250 medications, including Paxlovid and cancer therapies, will see price increases in the United States beginning ...
Deccan Chronicle6d
Expiry of Rs 12k cr patented US drugs a big opportunity for pharma
The top 10 patented drugs getting expired in the coming years in the US, include Pembrolizumab, sold under the brand name ...
Health Rounds: Surgery may be unnecessary for common precancerous breast condition
Early results from a clinical trial appear to confirm that most women with the precancerous breast condition known as ductal ...
precisionmedicineonline22d
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...
Yahoo Finance25d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
clinicaltrialsarena25d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...
Cancer Research25d
Palbociclib Dramatically Increases PFS in Metastatic Breast Cancer
The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...
Yahoo Finance26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...
ENDPOINTS NEWS26d
Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set
Pfiz­er touts Ibrance’s sta­tus as a stan­dard of care in HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer. Now the com­pa­ny wants to ex­pand to dou­ble-pos­i­tive pa ...
Benzinga.com26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer's PATINA trial shows IBRANCE boosts progression-free survival in HR+/HER2+ metastatic breast cancer by over 15 months. Median PFS reached 44.3 months with IBRANCE plus standard anti-HER2 ...
Yahoo Finance26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant ...